ResearcherActive in the last 2 years

EunJi Kim

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0000-9543-0780. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2025: 1 paper

Papers 1

Cetuximab-mediated antibody-dependent cell-mediated cytotoxicity enhances anti-tumor efficacy of patient-derived natural killer cells in pancreatic cancer. Co-author DOI 10.1016/j.biopha.2025.118714 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Eunsung Jun · 1 shared paper, 2025 · strength 0.27
- Paper Cetuximab-mediated antibody-dependent cell-mediated cytotoxicity enhances anti-tumor efficacy of patient-derived natura… DOI 10.1016/j.biopha.2025.118714 ↗
Seong‐Jin Kim · 1 shared paper, 2025 · strength 0.27
- Paper Cetuximab-mediated antibody-dependent cell-mediated cytotoxicity enhances anti-tumor efficacy of patient-derived natura… DOI 10.1016/j.biopha.2025.118714 ↗
Song Cheol Kim · 1 shared paper, 2025 · strength 0.27
- Paper Cetuximab-mediated antibody-dependent cell-mediated cytotoxicity enhances anti-tumor efficacy of patient-derived natura… DOI 10.1016/j.biopha.2025.118714 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.